99mTc-HYNIC-Fab(Bevacizumab): potential imaging agent for diagnosis of Non-Hodgkin's Lymphoma
DOI:
https://doi.org/10.35954/SM2017.36.2.2Keywords:
Lymphoma, Non-Hodgkin, VEGF, Fab 99m (Bevacizumab), Tc, HYNIC, Tumor AngiogenesisAbstract
Vascular endothelial growth factor (VEGF) is a key factor in tumor angiogenesis in many types of tumors, including non-Hodgkin's lymphoma (NHL). The aim of the present work is the radiolabeling of antigen binding fragments (Fab) of the 99m monoclonal antibody Bevacizumab with Tc and its evaluation as a potential imaging agent for NHL. To achieve this, VEGF expression was analyzed by flow cytometry in a NHL cell line (Toledo). Fragmentation was performed using papain and the Fab obtained were conjugated with NHS-HYNIC-Tfa and 99m radiolabeled with Tc. Radiochemical purity and stability were assayed. Biodistribution studies were performed in both healthy and NHL-bearing mice. Toledo cells were found to have elevated VEGF expression. Radiolabeling was performed in a rapid, simple, reproducible and stable manner, with radiochemical purities >90%. Biodistribution studies revealed significant renal and tumor uptake, indicating that the main route of elimination is renal. From the 99m results obtained we conclude that Tc-HYNIC-Fab (Bevacizumab) represents a potential imaging agent for VEGF expression associated with NHL.
Downloads
References
(1) Swerdlow AJ. Epidemiology of Hodgkin's disease and nonHodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 Suppl 1:S3-12.
(2) Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 15(12):1359-64.
(3) Rosen LS. VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances. The Oncologist 2005; 10(6):382-91.
(4) Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005; 17(6):611-6.
(5) Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endotelial growth factor
in lymphomas and Castelman disease. J Pathol 1997; 183(1):44-50.
(6) Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamtteo F,et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin´s lymphomas. Br J Cancer 1999; 79(5-6):965-70.
(7) Riley LB, Desai DC. The Molecular Basis of Cancer Development of Targeted Therapy. Surg Clin N Am 2009; 89(1):1-15.vii.
(8) Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Oncol 2006; 3(1):24-40.
(9) Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled Bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48(8):1313-1319.
(10) Stollman TH, Scheer MG, Leenders WP, Verrijp KN, Soede AC, Oyen Wj, et al. Specific imaging of VEGF-A expression with radiolabelled anti-VEGF monoclonal antibody. Int J Cancer 2008; 122(10):2310-4.
(11) Stollman TH, Scheer MG, Franssen GM, Verrijp KN, Oyen Wj, Ruers TJ, et al. Tumor accumulation of radiolabelled bevacizumab due to targeting of cell- and matrix-associated VEGF-Aisoforms. Cancer Biother Radiopharm 2009; 24(2):195-200.
(12) Chang SK, Rizvi I, Solban N, Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res 2008; 14(13):4146-53.
(13) Scheer MG, Stollman TH, Boerman OC, Verrijp KN, Sweep FC, Leenders PJ, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression. Eur J Cancer 2008; 44(13):1835-40.
(14) Camacho X, Calzada V, Fernández M, Alonso O, Chammas R, Riva E, et al. “177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma”. Curr Radiopharm 2017; 10(1):21-8.
(15) Camacho X, García MF, Calzada V, Fernández M, 99 Alonso O, Gambini JP, et al. “ mTc-labeled Bevacizumab vía HYNIC for Imaging of Melanoma”. J Anal Oncol 2014; 3(1):53-64.
(16) Camacho X, García MF, Calzada V, Fernández M, 99 Chabalgoity JA, Moreno M, et al. “[ mTc(CO3)]-Radiolabeled Bevacizumab: In vitro and in vivo Evaluation in a Melanoma Model”. Oncology 2013: 84(4):200-9.
(17) Camacho X, García MF, Calzada V, Fernández M, Porcal W, Alonso O, et al. “Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab”. Curr Radiopharm 2013; 6(1):12-9.
(18) Hurwitz H, Fehrenbacher L, Novotny W, Crtwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastic colorectal cancer. N Engl J Med 2004; 350(23):2335-42.
(19) Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti- vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57(20):4593-9.
(20) Jurisson S, Berning D, Jia W, Ma D. Coordination Compounds in Nuclear Medicine. Chem Rev 1993; 93(3):1137-56.
(21) Dilworth JR.; Parrottb JS. The biomedical chemistry of technetium and rhenium. Chem Soc Rev 1998; 27(1):43-55.
(22) Wu AM.; Olafsen T. Antibodies for molecular imaging in cancer. Cancer J 2008; 14(3):191-7.
(23) Calzada V, García MF, Alonso-Martínez LM, Camacho X, Goicochea E, Fernández M, et al. “Fab (nimotuzumab)-HYNIC-99mTc: Antibody fragmentation for molecular imaging agents”. Anticancer Agents Med Chem 2016; 16(9):1184-9.
(24) Hantowich DJ, Virzi F, Fogarasi M, Rusckowski M, Winnard P Jr. Can a Cysteine Challenge Assay Predict the In vivo Behavior of 99mTc-labeled Antibodies? Nuc Med Biol 1994; 21(8):1035-1044.
(25) Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-Human Polyclonal IgG Radiolabeled via the Hydrazino Nicotinamide Derivatives for Imaging Focal Sites of Infection in Rats. J Nuc Med 1990; 31(12):2022-2018.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Carolina Perroni, Ximena Camacho, María Fernanda García, Marcelo Fernández, Hugo Cerecetto, Juan Pablo Gambini, Eloisa Riva. Pablo Cabral. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
